Proteome SciencesPMSNF PS Ratio is 1.55 as of Jun. 27, 2026, which is 40% below its 10-year median of 2.59. The stock has 6 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Proteome Sciences ranks better than 72.64% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Proteome Sciences's share price is $0.02475.
Proteome Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02. Hence, Proteome Sciences's PS Ratio for today is 1.55.
The historical rank and industry rank for Proteome Sciences's PS Ratio or its related term are showing as below:
PMSNF'
s PS Ratio Range Over the Past 10 Years
Min: 0.94 Med: 2.59 Max: 22.22
Current: 1.43
During the past 13 years, Proteome Sciences's highest PS Ratio was 22.22. The lowest was 0.94. And the median was 2.59.
PMSNF's PS Ratio is ranked better than 72.64% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.78
vs PMSNF: 1.43
Proteome Sciences PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Proteome Sciences was -25.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -21.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -5.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.20% per year.
During the past 13 years, Proteome Sciences's highest 3-Year average Revenue per Share Growth Rate was 212.40% per year. The lowest was -43.50% per year. And the median was 10.10% per year.
Back to Basics: PS Ratio
Proteome Sciences (OTCPK:PMSNF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Proteome Sciences PS Ratio Related Terms
Proteome Sciences PS Ratio Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Proteome Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Proteome Sciences's Share Price of today is $0.02475.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Proteome Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Proteome Sciences (PMSNF) has a PS Ratio of 1.55 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Proteome Sciences and its competitors. This is 40% below median its historical median of 2.59. Over the past decade, Proteome Sciences' PS Ratio has ranged from 0.94 to 22.22. According to the industry distribution chart, Proteome Sciences ranks #55 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 27.4%.
Is Proteome Sciences' PS Ratio too high?
Proteome Sciences' current PS Ratio of 1.55 is 40% below median its 10-year median of 2.59. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 22.22. The Medical Diagnostics & Research industry median PS Ratio is 2.78. Proteome Sciences' value of 1.55 is 44.2% below this industry median. Based on the distribution chart, Proteome Sciences ranks #55 out of 201 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Proteome Sciences' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #55 out of 201 companies for PS Ratio. This puts Proteome Sciences in the upper half of its industry. The industry median PS Ratio is 2.78. Proteome Sciences' value of 1.55 is 44.2% below this benchmark. Historically, Proteome Sciences' own PS Ratio has ranged from 0.94 to 22.22 over the past decade. While the company's 10-year median is 2.59 vs. the industry median of 2.78, Proteome Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.78, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteome Sciences's current PS Ratio of 1.55 is 44.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Proteome Sciences and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteome Sciences's current PS Ratio is 1.55, which is 40% below median its own 10-year median of 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Proteome Sciences (PMSNF) has a current PS Ratio of 1.55. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 17.5% below its estimated fair value. The current PS Ratio is 1.55, which is 40% below median its 10-year median of 2.59 and 44.2% below the Medical Diagnostics & Research industry median of 2.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Proteome Sciences (PMSNF), the current PS Ratio is 1.55 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMSNF has been successfully added to your 